Key Points
- Insider buying: Giles Wilson bought 197 shares on Dec 11 at GBX 76 (total £149.72) and has made several small purchases in Oct–Nov at GBX 85–90, signaling continued insider accumulation.
- Stock snapshot: LON:DOCS trades near GBX 76.97 with a market cap of ~£743.8M, P/E 45.28 and a 52‑week range of GBX 43.02–100.87; analysts show a consensus rating of Moderate Buy (two Buy, two Hold) and a reported consensus price target of GBX 6,000.
- Recent results and outlook: Last quarter EPS was GBX (0.90) with a net margin of 7.89% and ROE of 18.91%, while sell‑side analysts forecast ~2.58 EPS for the current fiscal year.
Dr. Martens plc (LON:DOCS - Get Free Report) insider Giles Wilson bought 197 shares of the company's stock in a transaction on Thursday, December 11th. The stock was bought at an average price of GBX 76 per share, for a total transaction of £149.72.
Giles Wilson also recently made the following trade(s):
- On Tuesday, November 11th, Giles Wilson purchased 176 shares of Dr. Martens stock. The stock was purchased at an average price of GBX 85 per share, with a total value of £149.60.
- On Monday, October 13th, Giles Wilson purchased 167 shares of Dr. Martens stock. The shares were purchased at an average cost of GBX 89 per share, for a total transaction of £148.63.
- On Wednesday, October 8th, Giles Wilson bought 114 shares of Dr. Martens stock. The shares were acquired at an average cost of GBX 90 per share, for a total transaction of £102.60.
Dr. Martens Stock Performance
Shares of LON:DOCS opened at GBX 76.97 on Friday. The company has a market capitalization of £743.81 million, a price-to-earnings ratio of 45.28, a price-to-earnings-growth ratio of 6.40 and a beta of 0.11. Dr. Martens plc has a 52 week low of GBX 43.02 and a 52 week high of GBX 100.87. The company has a quick ratio of 1.13, a current ratio of 2.85 and a debt-to-equity ratio of 127.27. The firm has a 50 day moving average of GBX 84.81 and a 200 day moving average of GBX 82.45.
Dr. Martens (LON:DOCS - Get Free Report) last issued its quarterly earnings data on Thursday, November 20th. The company reported GBX (0.90) earnings per share for the quarter. Dr. Martens had a net margin of 7.89% and a return on equity of 18.91%. On average, sell-side analysts predict that Dr. Martens plc will post 2.5809394 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
DOCS has been the topic of several recent analyst reports. Berenberg Bank restated a "buy" rating on shares of Dr. Martens in a report on Thursday, November 27th. Peel Hunt reaffirmed a "buy" rating on shares of Dr. Martens in a report on Thursday, November 20th. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, Dr. Martens has a consensus rating of "Moderate Buy" and a consensus price target of GBX 6,000.
View Our Latest Stock Report on DOCS
About Dr. Martens
(
Get Free Report)
Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
